StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5-Chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo(2,3:6,7)oxepino(4,5-c)pyrrole

HCID 9903970
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
158018-50-9
Standard-SMILES
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
InChIKey
VSWBSWWIRNCQIJ-UHFFFAOYSA-N
Summenformel
C17H16ClNO
Durchschnittliche Molmasse
285,8 g/mol
Monoisotopische Masse
285,0920418

Überblick

5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole is an organic heterotetracyclic compound that is 2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole bearing methyl and chloro substituents at positions 2 and 5 respectively. It is an organochlorine compound, a cyclic ether, an organic heterotetracyclic compound and a tertiary amino compound.

Namen und Bezeichner

Bevorzugter Name
5-Chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo(2,3:6,7)oxepino(4,5-c)pyrrole
IUPAC
9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene

Namen und Synonyme

5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrroleCHEBI:712555-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo(2,3:6,7)oxepino(4,5-c)pyrrole5-Chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo(2,3:6,7)oxepino(4,5-c)pyrroleRefChem:302428cis-AsenapineAsenapine-d3158018-50-9SCHEMBL2221502CHEMBL3187365SCHEMBL29365680
Weitere Namen anzeigen
SCHEMBL30413463SCHEMBL30544842BDBM84994DTXSID50860813VSWBSWWIRNCQIJ-UHFFFAOYSA-NFXB84372QCA62178CAS_163091

Datenbank-Bezeichner

CAS
158018-50-9、65576-45-6
PubChem CID
9903970
DTXSID
DTXSID50860813
ChEMBL
CHEMBL3187365
ChEBI
CHEBI:71255

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,8
Polarare Oberfläche (TPSA)
12,5 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
0
Schwere Atome
20
Formalladung
0
Komplexität
363

Chemie und Industrie

Pharmakologische Informationen

Protein Binding95% protein bound
Pharmacodynamics · 1 Eintrag

Asenapine is a serotonin, dopamine, noradrenaline, and histamine antagonist in which asenapine possess more potent activity with serotonin receptors than dopamine. Sedation in patients is associated with asenapine's antagonist activity at histamine receptors. Its lower incidence of extrapyramidal effects are associated with the upregulation of D1 receptors. This upregulation occurs due to asenapine's dose-dependent effects on glutamate transmission in the brain. It does not have any significant activity with muscarinic, cholinergic receptors therefore symptoms associated with anticholinergic drug activity like dry mouth or constipation are not expected to be observed. Asenapine has a higher affinity for all aforementioned receptors compared to first-generation and second-generation antipsychotics except for 5-HT1A and 5-HT1B receptors.

Mechanism of Action · 1 Eintrag

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia.

Biological Half-Life24 hours (range of 13.4 - 39.2 hours)
Metabolism/MetabolitesAsenapine is oxidized via CYP1A2 and undergoes direct glucuronidation via UGT1A4. Oxidation via CYP1A2 is asenapine's primary mode of metabolism.
Absorption, Distribution and Excretion · 3 Einträge

Cmax, single 5 mg dose = 4 ng/mL (within 1 hour); Bioavailability, sublingual administration = 35%; Bioavailability, oral administration (swallowed) = <2%; Time to steady state, 5 mg = 3 days; Peak plasma concentration occurs within 0.5 to 1.5 hours. Doubling dose of asenapine results in 1.7-fold increase in maximum concentration and exposure. Drinking water within 2-5 minutes post administration of asenapine results in a decrease in exposure.

Zugehörige Reaktionen

13
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 63778
HRID 63778als Edukt
Reaktionsgleichung von HRID 63779
HRID 63779als Produkt
Reaktionsgleichung von HRID 63780
HRID 63780als Edukt
Reaktionsgleichung von HRID 63781
HRID 63781als Produkt
Reaktionsgleichung von HRID 63782
HRID 63782als Edukt
Reaktionsgleichung von HRID 176812
HRID 176812als Produkt
Reaktionsgleichung von HRID 243629
HRID 243629als Produkt
Reaktionsgleichung von HRID 290256
HRID 290256als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Nikkaji
J608.443E

Urine (50%) and feces (50%)

20-25 L/kg